#TBCPartner Sarepta Therapeutics is revolutionizing treatment for Duchenne muscular dystrophy so more kids like Hiram can continue to do the things they love – from playing with Legos to joining Scouting America. Hiram was the first child in the country to receive Sarepta’s ELEVIDYS, the only approved gene therapy for Duchenne, after its approval by the FDA in June 2023. A year later, he’s growing stronger and keeping up with his friends in his Virginia Cub Scout pack. Read his heartwarming story here: https://lnkd.in/eUmTJzQa
Ten Bridge Communications
Public Relations and Communications Services
Boston, MA 4,552 followers
We guide biotech through the big moments.
About us
We work with biotech innovators at all stages of growth and development, whether they are launching anew or advancing a potentially transformative medicine through regulatory approval and beyond. Our work is guided by a deep curiosity about our partners’ science and patient focus and a commitment to elevating them and their message to the world. Relationships – both with our partners and across biotech – are critical ingredients of our success.
- Website
-
https://www.tenbridgecommunications.com/
External link for Ten Bridge Communications
- Industry
- Public Relations and Communications Services
- Company size
- 11-50 employees
- Headquarters
- Boston, MA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Company launches, corporate branding & creative services, strategic communications planning & execution, patient engagement & advocacy support, product approval & launch communications, and milestone-related media and communications
Locations
-
Primary
One Beacon Street
8th Floor
Boston, MA 02108, US
Employees at Ten Bridge Communications
Updates
-
#TBCPartner Clasp Therapeutics is on fire! Just five months after launching, Clasp is a DC Inno 2024 Fire Award winner for their work developing next generation T cell engagers.
We’re honored to announce that Clasp Therapeutics has been recognized with a DC Fire Award! This award highlights the companies driving innovation and growth in the Greater Washington area, and we’re proud to be among them. Thank you to our incredible team and partners for making this possible. Read more about the award and our work in the feature article. #Innovation #Biotech #CancerResearch #DCFireAwards #ClaspTherapeutics https://lnkd.in/ehu_pcKi
-
-
We had the honor of working with #TBCPartner HC Bioscience, Inc. and the Make-A-Wish® Massachusetts and Rhode Island to grant 10-year-old Alex’s wish to be an HC Bioscience researcher for a day. Alex and his family travelled from Texas to Boston to fulfill his wish to study therapeutic tRNAs – a modality being developed to treat his own type of Duchenne muscular dystrophy. Through an eventful day of experiments, Alex collaborated with the HC Bioscience team to demonstrate how tRNA-based medicines have the potential to overwrite mutations that result in shortened proteins and, in his case, nonsense mutation Duchenne muscular dystrophy (nmDMD). Everyone involved was struck by Alex’s curiosity and imagination as well as the love and dedication of his family. It is humbling to be part of moments like these that highlight the power of science to inspire, bring communities together, and ultimately transform lives through new therapies.
Last week, we had the honor of fulfilling a wish for our amazing guest scientist of the day, Alex! Through the Make-A-Wish® Massachusetts and Rhode Island foundation, Alex was able to visit our headquarters in Boston and learn more about our drug development efforts for Duchenne muscular dystrophy, which specifically targets the nonsense mutation that personally impacts him. Alex enjoyed a tour of the lab and participated in a variety of experiments, such as visualizing plasmids in agarose gel and examining muscle cells through a microscope. Following this, Alex presented his findings and was recognized as a “Rising Science Star!” We are so appreciative that Alex’s family was able to make the trip to Boston for this special day. It was truly an unforgettable experience. Thank you to Make-A-Wish America, Sean Holleran, Make-A-Wish North Texas and Make-A-Wish® Southern Florida as well as our dedicated team whose passion and commitment make moments like this possible. In the coming weeks, we’ll be sharing more highlights from this amazing day! #MakeaWish #DMD
-
We have the privilege of working alongside companies who are making a tremendous impact on patients. Over the last few months, we've seen many of our #TBCPartners, including Sarepta Therapeutics, Verona Pharma, and X4 Pharmaceuticals, receive FDA approvals for their life-changing medicines. Their efforts and dedication are transforming what’s possible in the world of biotech, and we’re thrilled to be a key player in continuing to share their stories.
-
#TBCPartner AIRNA today announced the successful closing of an oversubscribed $60 million financing round, an important step forward for their work to advance a broad RNA editing pipeline, including their lead program for alpha-1 antitrypsin deficiency (AATD). Read more in today’s piece by Alex Philippidis at Genetic Engineering & Biotechnology News:
AIRNA, a developer of RNA editing therapies whose lead program targets Alpha-1 antitrypsin deficiency (AATD) said today it has closed an oversubscribed $60 million Series A financing, with plans that include advancing the treatment into the clinic next year. In addition to launching clinical trials assessing the AATD candidate, AIRNA says it will use proceeds from the Series A to build up a pipeline that is envisioned to go beyond rare diseases. https://ow.ly/2i9B50SO4kw
RNA Editing Therapy Developer Closes $60M Series A Financing
genengnews.com
-
April was a groundbreaking month for #TBCPartner X4 Pharmaceuticals, marking the company’s first-ever FDA approval for a product indicated in patients with WHIM syndrome, an ultra-rare disease affecting nearly 1,000 people in the U.S. We had the privilege of partnering with X4 on its communication efforts around the announcement. Some of the highlights include: - Serving as an extension of the team to support strategy and execution - Ensuring that the media was fully informed of the news leading up to the decision date - Providing media perspective from patients and physicians on the severity of WHIM syndrome and the unmet need that has gone unaddressed for decades This critical moment for X4 served as a catalyst for all that’s to come for the company and the rare disease community. Read more here: https://lnkd.in/e3sUaSuX
X4 Pharmaceuticals, Inc. » Ten Bridge Communications
tenbridgecommunications.com
-
Ten Bridge Communications reposted this
Last week, we hosted a group from Ten Bridge Communications at Red Wing Bay in Needham to remove invasive Water Chestnuts from the Charles River! Together, this team removed an incredible 106 baskets of Water Chestnuts, which is an estimated 2,226 lbs of plants! Thank you to this group for their hard work and continued dedication to alleviating the environmental stresses that invasive plants such as Water Chestnut can cause.
-
-
Exciting news for #TBCPartner SOTIO Biotech which recently announced its latest partnership, further expanding its next-generation antibody-drug conjugate pipeline for the treatment of solid tumors. This marks SOTIO’s fourth partnership for the development of ADCs – a highly specific and potent treatment class.
Today we announced a research collaboration and exclusive licensing agreement with Biocytogen to expand our antibody-drug conjugate pipeline. This agreement enables us to license multiple fully human bispecific antibodies generated with Biocytogen’s RenLite® platform for developing next-generation ADCs targeting solid #tumors. Read more in our press release: https://lnkd.in/eYvKfxub #biotechnology #ADCs #CancerTherapy #jsmePPF
-
-
Last week, some members of our team volunteered with the Charles River Watershed Association to remove invasive water chestnuts from the Charles River here in Massachusetts. Water chestnuts are an invasive aquatic plant found in the Charles River. They are rosette shaped and fast growing, thus blocking out other life in the river. Thanks to the CRWAs efforts, they have removed over 100 tons of water chestnuts from the Charles. Our team helped remove another 106 baskets of water chestnuts. Well done team, and thank you to the CRWA for another amazing volunteer experience!
-
-
In biotech communications, understanding your audience can evolve as quickly as your scientific innovations. This makes staying up to date on audience sentiment crucial. Whether it’s ensuring that healthcare providers understand your science as an FDA decision approaches, or how the investor community perceives your competitive advantages with an impending IPO, these insights can be essential data points for your communications strategy. With that in mind, the question becomes, how? Enter social listening. Recently, TBC’s Digital Marketing Manager Hannah Clark discussed the value of social listening in biotech. She covered: - What social listening entails - How it can play out in the biotech landscape - What essential tactics to use to optimize your social listening strategy Give it a read on our blog: https://lnkd.in/eYd_8eht
Listen Up: The Benefits of Social Listening for Biotech Companies » Ten Bridge Communications
tenbridgecommunications.com